Pharmaceutical Company Pneuma Respiratory Raises $8.3 Million Series A
BOONE, N.C., July 18, 2018 /PRNewswire/ -- Pneuma Respiratory, Inc., which has developed PNEUMAHALERtm,, the first breath-activated digital inhaler (BDI), has raised $8.3 million in a Series A financing round.
Pneuma Respiratory, Inc. ("Pneuma") has developed the PNEUMAHALERtm Breath Activated Digital Inhaler (BDI) to solve the problems of existing metered dose, dry- powder, and soft-mist inhalers to improve the efficacy of currently available airway medications. PNEUMAHALER BDI ("PNEUMAHALER") is the first pulmonary inhaler to merge advanced droplet ejector technology with digitally controlled breath-actuation, and package it in a lightweight, pocket-sized device. Pneuma's go-to-market strategy is to marry the powerful technology of its digital platform with off-patent drugs and create more efficacious treatments for asthma and COPD. Pneuma's strategy aims to de-risk its clinical and regulatory pathway and create value by rebranding off-patent therapeutic treatments within its patented PNEUMAHALER system to improve treatments for patients in the $39+ billion global asthma + COPD market.
Eric Hunter, CEO and Founder of Pneuma Respiratory stated, " We are extremely gratified by the response to our Series A capital raise and look forward to continuing Pneuma's mission of developing greatly improved therapeutic treatments for patients who suffer from asthma and COPD."
About Pneuma Respiratory
Launched in 2015, Pneuma Respiratory is a pharmaceutical company based in Boone, North Carolina. With a global team of researchers, physicians, designers and engineers, Pneuma has created PNEUMAHALERtm, the first fully integrated digital breath activated inhaler. The inhaled delivery system has integrated Bluetooth technology to provide feedback on drug delivery to patients, family members and health care providers. Using Pneuma's [proprietary/patented] digital droplet ejector technology, Pneuma's device, although currently available for investigational purposes only, has the potential to ultimately deliver a spectrum of novel therapies, including biologics, through the lungs. For more information visit www.pneumarespiratory.com
Contact:
Eric Hunter
8284346433
SOURCE Pneuma Respiratory
These press releases may also interest you
|
News published on and distributed by:
